REC-4881 is under clinical development by Recursion Pharmaceuticals and currently in Phase I for Hepatocellular Carcinoma. According to GlobalData, Phase I drugs for Hepatocellular Carcinoma have an 81% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how REC-4881’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
REC-4881 is under development for the treatment of familial adenomatous polyposis, hepatocellular carcinoma and ovarian cancer. The drug candidate is an orally bioavailable small-molecule inhibitor of MEK1 and MEK2 (MEK1/2) with potential antineoplastic activity.
It was under development for the treatment of solid tumors (non-hematologic malignancy) and metastatic melanoma, hereditary cancer syndrome, solid tumors.
Recursion Pharmaceuticals overview
Recursion Pharmaceuticals (Recursion) is an artificial intelligence (AI)-driven biopharmaceutical company. It harnesses the potential of applying machine learning (ML) to complex biology to advance novel treatment options for diseases with high unmet medical needs. The company houses over four petabytes of biological images on its robotics platform which applies advanced ML to identify drug candidates and provide insights on potential toxicity, and mechanisms of action. It is advancing a pipeline of cardiovascular, metabolic, oncology, immunology, neuroscience, and infectious diseases models. The company also offers target discovery and lead optimization services to its partner companies for furthering their clinical investigation. Recursion is headquartered in Salt Lake City, Utah, the US.
For a complete picture of REC-4881’s drug-specific PTSR and LoA scores, buy the report here.